Buzz Stocks: Nike Inc, Adamas Pharmaceuticals Inc, and Celgene Corporation

Today's stocks to watch include Nike Inc (NYSE:NKE), Adamas Pharmaceuticals Inc (NASDAQ:ADMS), and Celgene Corporation (NASDAQ:CELG)

by Josh Selway

Published on Dec 23, 2015 at 9:29 AM

Updated on Dec 23, 2015 at 9:32 AM

The Dow looks ready for a third straight win, with oil prices on the mend. Among the equities in focus are athletics retailer Nike Inc (NYSE:NKE), as well as biotechs Adamas Pharmaceuticals Inc (NASDAQ:ADMS), and Celgene Corporation (NASDAQ:CELG).

NKE is likely to make some recent option bulls very happy today, with the shares set for a 2.8% pop at the open, following the firm's standout quarterly report. Specifically, the blue chip beat Wall Street's earnings expectations, while future orders also topped forecasts. The potential gap higher would mark Nike Inc's fourth straight post-earnings move to the upside, and should have the stock in record-high territory, after it closed Tuesday at $131.85 -- over 37% higher year-to-date. This morning, analysts -- who were already bullish -- are raising their expectations. No fewer than seven brokerage firms upped their price targets, with D.A. Davidson setting the bar the highest at $156.

ADMS saw promising results during a late-stage study from its experimental treatment of levodopa-induced dyskinesia (LID), news that has the shares 33.5% higher before the bell. The stock should now easily be able to overcome the $17 area that's been acting as overhead resistance during the past two months, while also moving back into positive year-to-date territory after its settlement at $16.86 on Tuesday. We'll see if today's price action can shake some short sellers. The almost 500,000 Adamas Pharmaceuticals Inc shares that are sold short represent over six days' worth of buying power, at normal daily volumes.

CELG is looking at an 8.4% surge when the market opens -- which'll have it back in the black for 2015 -- after the drug company settled a patent dispute related to generic versions of its cancer treatment, Revlimid. On the Street, analysts have had bullish aspirations for the biotech stock. Thirteen of the 15 brokerage firms that track Celgene Corporation say it's a "buy," with not a single "sell" rating in sight. What's more, CELG's consensus 12-month price target of $142.75 stands in never-before-charted territory, and represents a 28.4% premium to last night's close at $111.14.

Follow @Schaeffers

A Schaeffer's exclusive

6 Sectors for Summer

Access your FREE insider report before it's too late!

Browse By Topic

View All Articles By Date

Partnercenter

^NEW!Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers. Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.